Biodel's VIAject insulin Phase 3 study results to be presented at international diabetes conference in Basel

Biodel, Inc. (Nasdaq: BIOD) announced today that its chief executive officer, Dr. Sol Steiner, will present results from the company’s two Phase 3 studies with VIAject® ultra-rapid-acting recombinant human insulin in a platform presentation at the 3^rd International Conference on Advanced Technologies and Treatments for Diabetes in Basel, Switzerland, on Friday, February 12, 2010, at 1pm central European time. The presentation, entitled “Clinical Findings for Patients Treated with VIAject®, An Ultra-Rapid Acting Formulation of Recombinant Human Insulin,” will review and update key data from the VIAject® clinical development program. Dr. Steiner’s presentation will be available on the company’s website, www.Biodel.com, after the presentation.

“Clinical Findings for Patients Treated with VIAject®, An Ultra-Rapid Acting Formulation of Recombinant Human Insulin”